lung cancer

News

Keytruda drives another strong Merck quarter, but what’s nex...

Merck & Co/MSD’s first quarter followed the predictable pattern of a surge in sales on the back of immuno-oncology blockbuster Keytruda, but analysts are starting to ask how the company

News

AZ gets NICE nod for ‘big advance’ Imfinzi in lung cancer

AstraZeneca has won the backing of NICE for its cancer immunotherapy Imfinzi for non-small cell lung cancer (NSCLC), with the drug made available via the Cancer Drugs Fund for now.

News

Roche's Tecentriq gains new US lung cancer indication

Roche’s Tecentriq (atezolizumab) cancer immunotherapy has gained a new indication in the US, after the FDA granted it a licence in a difficult to treat form of lung cancer in combination wi

News

Lilly's Cyramza hits mark in first-line lung cancer trial

Eli Lilly has produced phase 3 data that supports use of its Cyramza combined with Roche's Tarceva in first-line non-small cell lung cancer with EGFR mutations, paving the way for filings w

News

Two new cancer Priority Reviews for Roche

Roche has announced that the FDA has granted Priority Review to two of its drugs – personalised lung cancer medicine entrectinib and lymphoma treatment polat

News

J&J pays $3.4 billion for robotics firm Auris

Johnson & Johnson’s rumoured interest in Auris Health has been confirmed with a $3.3 billion buyout deal that boosts the group’s position in the fast-growing surgical robotics market.

Keytruda drives another strong Merck quarter, but what’s nex...

AZ gets NICE nod for ‘big advance’ Imfinzi in lung cancer

Roche's Tecentriq gains new US lung cancer indication

Lilly's Cyramza hits mark in first-line lung cancer trial

Two new cancer Priority Reviews for Roche

J&J pays $3.4 billion for robotics firm Auris

Ipsen' Bylvay fluffs its lines in biliary atresia trial

Discover a new era of healthcare panel engagement: Grounded ...

lung cancer

Editor's Picks